Genetically engineered CAR NK cells display selective cytotoxicity against FLT3‐positive B‐ALL and inhibit in vivo leukemia growth-Reference-Cited by-同舟云学术

Genetically engineered CAR NK cells display selective cytotoxicity against FLT3‐positive B‐ALL and inhibit in vivo leukemia growth

Published:2019-03-24 Issue: Volume: Page:
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Oelsner Sarah¹,Waldmann Anja¹,Billmeier Arne¹,Röder Jasmin¹²,Lindner Aline¹,Ullrich Evelyn³⁴,Marschalek Rolf⁵,Dotti Gianpietro⁶,Jung Gundram⁷⁸⁹,Große‐Hovest Ludger¹⁰,Oberoi Pranav¹,Bader Peter³,Wels Winfried S.¹²⁹¹¹^ORCID

Affiliation:

1. Institute for Tumor Biology and Experimental TherapyGeorg‐Speyer‐Haus Frankfurt Germany

2. Frankfurt Cancer InstituteGoethe University Frankfurt Germany

3. Division for Stem Cell Transplantation and Immunology, Hospital for Children and AdolescentsGoethe University Frankfurt Germany

4. LOEWE Center for Cell and Gene TherapyGoethe University Frankfurt Germany

5. Institute of Pharmaceutical BiologyGoethe University Frankfurt Germany

6. Lineberger Comprehensive Cancer Center and Department of Microbiology and ImmunologyUniversity of North Carolina Chapel Hill NC

7. Department of ImmunologyEberhard Karls University Tübingen Germany

8. German Cancer Consortium (DKTK)Partner Site Tübingen Tübingen Germany

9. German Cancer Research Center (DKFZ) Heidelberg Germany

10. SYNIMMUNE GmbH Tübingen Germany

11. German Cancer Consortium (DKTK)Partner Site Frankfurt/Mainz Frankfurt Germany

Funder

Hessen State Ministry of Higher Education, Research and the Arts; LOEWE Center for Cell and Gene Therapy Frankfurt

Hessen State Ministry of Higher Education, Research and the Arts; LOEWE Center Frankfurt Cancer Institute

Stiftung Polytechnische Gesellschaft, Frankfurt am Main

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32269

Reference55 articles.

1. B‐acute lymphoblastic leukemia/lymphoblastic lymphoma;Loghavi S;Am J Clin Pathol,2015

2. Childhood acute lymphoblastic leukemia: progress through collaboration;Pui CH;J Clin Oncol,2015

3. Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin‐Frankfurt‐Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen;Rytting ME;Am J Hematol,2016

4. Targeted therapy with the T‐cell‐engaging antibody blinatumomab of chemotherapy‐refractory minimal residual disease in B‐lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia‐free survival;Topp MS;J Clin Oncol,2011

5. Phase II trial of the anti‐CD19 bispecific T cell‐engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B‐precursor acute lymphoblastic leukemia;Topp MS;J Clin Oncol,2014

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy;Journal of Translational Medicine;2024-08-05

2. Extracellular Vesicles and Immune System Function: Exploring Novel Approaches to Colorectal Cancer Immunotherapy;Biomedicines;2024-07-03

3. Advances in CAR-NK cell therapy for hematological malignancies;Frontiers in Immunology;2024-06-28

4. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies;Biological Chemistry;2024-05-21

5. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases;Medical Oncology;2024-04-24